Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1267_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
15 Мб
Скачать
☆
124
37. Hooper LV, Littman DR, Macpherson AJ.Interactions between the microbiota and the immune
system. Science. 2012;336(6086):1268–73.
38. Takeuchi O, Akira S.Pattern recognition receptors and inammation. Cell. 2010;140(6):805–20.
39. Burke JP, Cunningham MF, Watson RW, Docherty NG, Coffey JC, O’Connell PR.Bacterial
lipopolysaccharide promotes probrotic activation of intestinal broblasts. Br J Surg. 2010;97(7):1126–34.
40. Burke JP, Watson RW, Mulsow JJ, Docherty NG, Coffey JC, O’Connell PR.Endoglin nega-
tively regulates transforming growth factor beta1-induced probrotic responses in intestinal broblasts. Br J Surg. 2010;97(6):892–901.
41. Miyazaki H, Kobayashi R, Ishikawa H, Awano N, Yamagoe S, Miyazaki Y, Matsumoto
T.Activation of COL1A2 promoter in human broblasts by Escherichia coli. FEMS Immunol Med Microbiol. 2012;65(3):481–7.
42. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC,
Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented lamentous bacteria. Cell. 2009;139(3):485–98.
43. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM, Glickman JN,
Garrett WS. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–73.
44. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ.Review article: the
role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104–19.
45. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer
K, Coffer PJ, Rudensky AY.Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–5.
46. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C,
Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446–50.
47. Pacheco RG, Esposito CC, Muller LC, Castelo-Branco MT, Quintella LP, Chagas VL, de Souza
HS, Schanaider A.Use of butyrate or glutamine in enema solution reduces inammation and brosis in experimental diversion colitis. World J Gastroenterol. 2012;18(32):4278–87.
48. Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol.
2011;12(1):5–9.
49. Boyapati RK, Rossi AG, Satsangi J, Ho GT.Gut mucosal DAMPs in IBD: from mechanisms
to therapeutic implications. Mucosal Immunol. 2016;9(3):567–82.
50. Wu F, Chakravarti S. Differential expression of inammatory and brogenic genes and
their regulation by NF-kappaB inhibition in a mouse model of chronic colitis. J Immunol. 2007;179(10):6988–7000.
51. Li Y, Jiang D, Liang J, Meltzer EB, Gray A, Miura R, Wogensen L, Yamaguchi Y, Noble
PW.Severe lung brosis requires an invasive broblast phenotype regulated by hyaluronan and CD44. J Exp Med. 2011;208(7):1459–71.
52. Soroosh A, Albeiroti S, West GA, Willard B, Fiocchi C, de la Motte CA.Crohn’s disease
broblasts overproduce the novel protein KIAA1199 to create proinammatory hyaluronan fragments. Cell Mol Gastroenterol Hepatol. 2016;2(3):358–68. e354.
53. Welter-Stahl L, da Silva CM, Schachter J, Persechini PM, Souza HS, Ojcius DM, Coutinho-Silva
R.Expression of purinergic receptors and modulation of P2X7 function by the inammatory cytokine IFNgamma in human epithelial cells. Biochim Biophys Acta. 2009;1788(5):1176–87.
54. Souza CO, Santoro GF, Figliuolo VR, Nanini HF, de Souza HS, Castelo-Branco MT, Abalo
AA, Paiva MM, Coutinho CM, Coutinho-Silva R. Extracellular ATP induces cell death in human intestinal epithelial cells. Biochim Biophys Acta. 2012;1820(12):1867–78.
55. Chen L, Brosnan CF.Regulation of immune response by P2X7 receptor. Crit Rev Immunol.
2006;26(6):499–513.
C. Bernardazzi et al.
8 Environmental Factors andTheir Inuence onIntestinal Fibrosis
56. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta
release by the ATP-gated P2X7 receptor. EMBO J. 2006;25(21):5071–82.
57. Neves AR, Castelo-Branco MT, Figliuolo VR, Bernardazzi C, Buongusto F, Yoshimoto A,
Nanini HF, Coutinho CM, Carneiro AJ, Coutinho-Silva R, de Souza HS.Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn’s disease. Inamm Bowel Dis. 2014;20(3):444–57.
58. Marques CC, Castelo-Branco MT, Pacheco RG, Buongusto F, do Rosario A Jr, Schanaider
A, Coutinho-Silva R, de Souza HS.Prophylactic systemic P2X7 receptor blockade prevents experimental colitis. Biochim Biophys Acta. 2014;1842(1):65–78.
59. Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, Picariello L,
Cazzola P, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender SL.Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut. 2009;58(6):777–89.
60. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT.Blocking
Smad7 restores TGF-beta1 signaling in chronic inammatory bowel disease. J Clin Invest. 2001;108(4):601–9.
61. Stevens EA, Mezrich JD, Bradeld CA.The aryl hydrocarbon receptor: a perspective on
potential roles in the immune system. Immunology. 2009;127(3):299–311.
62. Zhu C, Xie Q, Zhao B. The role of AhR in autoimmune regulation and its potential as a
therapeutic target against CD4 T cell mediated inammatory disorder. Int J Mol Sci. 2014;15(6):10116–35.
63. Busbee PB, Rouse M, Nagarkatti M, Nagarkatti PS.Use of natural AhR ligands as potential
therapeutic modalities against inammatory disorders. Nutr Rev. 2013;71(6):353–69.
64. Suwara MI, Green NJ, Borthwick LA, Mann J, Mayer-Barber KD, Barron L, Corris PA, Farrow
SN, Wynn TA, Fisher AJ, Mann DA.IL-1alpha released from damaged epithelial cells is suf­cient and essential to trigger inammatory responses in human lung broblasts. Mucosal Immunol. 2014;7(3):684–93.
65. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL.Identication of a key path-
way required for the sterile inammatory response triggered by dying cells. Nat Med. 2007;13(7):851–6.
66. Elkon KB.IL-1alpha responds to necrotic cell death. Nat Med. 2007;13(7):778–80.
67. Bersudsky M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S, Rider P,
Kaplanov I, Aychek T, Dinarello CA, Apte RN, Voronov E. Non-redundant properties of IL-1alpha and IL-1beta during acute colon inammation in mice. Gut. 2014;63(4):598–609.
68. Scarpa M, Kessler S, Sadler T, West G, Homer C, McDonald C, de la Motte C, Fiocchi C,
Stylianou E. The epithelial danger signal IL-1alpha is a potent activator of broblasts and reactivator of intestinal inammation. Am J Pathol. 2015;185(6):1624–37.
69. Scarpa M, Stylianou E. Epigenetics: concepts and relevance to IBD pathogenesis. Inamm
Bowel Dis. 2012;18(10):1982–96.
70. Koukos G, Polytarchou C, Kaplan JL, Oikonomopoulos A, Ziring D, Hommes DW, Wahed
R, Kokkotou E, Pothoulakis C, Winter HS, Iliopoulos D.A microRNA signature in pediatric ulcerative colitis: deregulation of the miR-4284/CXCL5 pathway in the intestinal epithelium. Inamm Bowel Dis. 2015;21(5):996–1005.
71. Barnett M, Bermingham E, McNabb W, Bassett S, Armstrong K, Rounce J, Roy N.Investigating
micronutrients and epigenetic mechanisms in relation to inammatory bowel disease. Mutat Res. 2010;690(1-2):71–80.
72. Cooke J, Zhang H, Greger L, Silva AL, Massey D, Dawson C, Metz A, Ibrahim A, Parkes
M. Mucosal genome-wide methylation changes in inammatory bowel disease. Inamm Bowel Dis. 2012;18(11):2128–37.
73. Nimmo ER, Prendergast JG, Aldhous MC, Kennedy NA, Henderson P, Drummond HE,
Ramsahoye BH, Wilson DC, Semple CA, Satsangi J. Genome-wide methylation proling in Crohn’s disease identies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway. Inamm Bowel Dis. 2012;18(5):889–99.
125
126
74. Sadler T, Scarpa M, Rieder F, West G, Stylianou E.Cytokine-induced chromatin modications
of the type I collagen alpha 2 gene during intestinal endothelial-to-mesenchymal transition. Inamm Bowel Dis. 2013;19(7):1354–64.
75. Sadler T, Bhasin JM, Xu Y, Barnholz-Sloan J, Chen Y, Ting AH, Stylianou E.Genome-wide
analysis of DNA methylation and gene expression denes molecular characteristics of Crohn’s disease-associated brosis. Clin Epigenetics. 2016;8:30.
76. Pekow JR, Kwon JH. MicroRNAs in inammatory bowel disease. Inamm Bowel Dis.
2012;18(1):187–93.
77. Zhao Y, Ma T, Chen W, Chen Y, Li M, Ren L, Chen J, Cao R, Feng Y, Zhang H, Shi
R.MicroRNA-124 promotes intestinal inammation by targeting aryl hydrocarbon receptor in Crohn’s disease. J Crohns Colitis. 2016;10(6):703–12.
78. Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA.Severe
spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732–8.
79. Ianiro G, Bibbo S, Montalto M, Ricci R, Gasbarrini A, Cammarota G.Systematic review: sprue-
like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16–23.
80. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE.Scleromyxoedema-like
cutaneous diseases in renal-dialysis patients. Lancet. 2000;356(9234):1000–1.
81. Cowper SE, Bucala R.Nephrogenic brosing dermopathy: suspect identied, motive unclear.
Am J Dermatopathol. 2003;25(4):358.
82. Ting WW, Stone MS, Madison KC, Kurtz K.Nephrogenic brosing dermopathy with systemic
involvement. Arch Dermatol. 2003;139(7):903–6.
83. Grobner T.Gadolinium—a specic trigger for the development of nephrogenic brosing der-
mopathy and nephrogenic systemic brosis? Nephrol Dial Transplant. 2006;21(4):1104–8.
84. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS.Nephrogenic
systemic brosis: suspected causative role of gadodiamide used for contrast-enhanced mag­netic resonance imaging. J Am Soc Nephrol. 2006;17(9):2359–62.
85. Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, Shah
SV. Nephrogenic systemic brosis, gadolinium, and iron mobilization. N Engl J Med. 2007;357(7):720–2.
86. Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM.Gadolinium contrast agent-induced
CD163+ ferroportin+ osteogenic cells in nephrogenic systemic brosis. Am J Pathol. 2013;183(3):796–807.
87. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, Brown HH, Shah
SV.Cardiac and vascular metal deposition with high mortality in nephrogenic systemic bro­sis. Kidney Int. 2008;73(12):1413–8.
88. Halliwell B.The wanderings of a free radical. Free Radic Biol Med. 2009;46(5):531–42.
89. Stubbleeld MD.Radiation brosis syndrome: neuromuscular and musculoskeletal complica-
tions in cancer survivors. PM R. 2011;3(11):1041–54.
90. Deas SD, Huprikar N, Skabelund A.Radiation exposure and lung disease in today’s nuclear
world. Curr Opin Pulm Med. 2017;23(2):167–72.
91. Harb AH, Abou Fadel C, Sharara AI. Radiation enteritis. Curr Gastroenterol Rep.
2014;16(5):383.
92. Spitz DR, Hauer-Jensen M.Ionizing radiation-induced responses: where free radical chemis-
try meets redox biology and medicine. Antioxid Redox Signal. 2014;20(9):1407–9.
C. Bernardazzi et al.
Chapter 9
Animal Models andSources ofMesenchymal Cells inIntestinal Fibrosis
DominikBettenworth
Abstract Intestinal brosis is a common complication in patients with Crohn’s
disease (CD) that often results in an impaired quality of life of affected patients. In the absence of specic anti-brotic medical therapy, patients with stricturing CD often have to undergo invasive endoscopic treatment approaches or surgical inter­vention. Beside the lack of medical treatment options for stricturing CD, the diag­nostic work-up is hampered by the limited accuracy of methods for detection, characterization and grading of intestinal brosis. Therefore, functional studies as well as studies evaluating novel diagnostic and therapeutic approaches for strictur­ing CD are urgently needed and require appropriate animal models as a prerequisite. Over recent years, several animal models for intestinal brosis have been estab­lished that allow for evaluation of experimental brosis at different stages and in the context of different pro-brotic triggers. In the following chapter, a variety of ani­mals models will be presented, specic advantages and disadvantages will be emphasized and the overall relevance and applicability of these models to study human brostenotic IBD will be discussed.
In the second part of the chapter, different sources of mesenchymal cells, one of the key executor of intestinal brogenesis, will be discussed. In addition to well known mechanism such as proliferation and migration of broblasts, novel aspects such as cellular transdifferentiation including epithelial- and endothelial to mesen­chymal transition will be described. Finally, novel techniques to trafc cellular fate will be displayed.
Keywords Animal model · Intestinal inammation · Trinitrobenzene sulfonic acid
· Dextran sodium sulfate · T cell transfer · Senescence accelerated mice P1/Yit mouse · Salmonella typhimurium · Radiation · Postoperative brosis · Heterotopic intestinal transplant model · Mesenchymal cells · Fibroblast · Myobroblasts · Epithelial to mesenchymal transition · Endothelial to mesenchymal transition · Bone-marrow stem cell · Stellate cells · Pericyte · Fibrocyte
D. Bettenworth Department of Medicine B, Gastroenterology and Hepatology, University of Muenster, Muenster, Germany e-mail: dominik.bettenworth@ukmuenster.de
F. Rieder (ed.), Fibrostenotic Inammatory Bowel Disease,
https://doi.org/10.1007/978-3-319-90578-5_9
127© Springer International Publishing AG, part of Springer Nature 2018
128
D. Bettenworth
9.1 Animal Models ofIntestinal Fibrosis
Animal models may never completely display the complex pathophysiology of human disease and are inevitably associated with methodological limitations. However, they represent one of the best available approaches to emerge the patho­physiological understanding as well as to test novel diagnostic and therapeutic approaches. Furthermore, preclinical data gained from animal models can serve as a valuable and cost-saving rationale for subsequent studies in human patients. Animal models for colitis have been introduced and studied for several decades, however, these models have been predominantly applied to evaluate the involve­ment of the immune system, the microbiota and inammatory alterations in the context of inammatory bowel disease (IBD) [1–3]. While not every colitis model is per se appropriate to equally study intestinal brosis, there is a growing body of evidence demonstrating that several of the available colitis models qualify as mod­els of intestinal brosis as well [4, 5]. In the following charpter, available brosis models will be categorized according to the induction of brosis.
Spontaneous models of intestinal brosis are particularly promising since they do not depend on exogenous stimulation. The senescence accelerated mice (SAM) P1/Yit mouse starts to develop a spontaneous enteric inammation in the ileum within 10weeks after birth and reveals a 100% penetrance of brosis by 30weeks after birth [6]. Beside the ileal disease location, which is the most frequent location in human CD patients, SAMP1/Yit mice depict further CD-like alterations such as a transmural and segmental injury accompanied by perianal lesions including stula development as well as granulomas in the mucosa and submucosa [6, 7]. Microbial factors are not crucial for this model as SAMP1/Yit mice do not develop inamma­tion under pathogen-free conditions. Functional studies have revealed that the inammation in the early phase of this model appears to be mediated by CD4 leading to a Th-1-like cytokine prole [8] while the chronic phase is characterized by Th2 responses [9]. A major drawback of this model is the low breeding rate and the limited commercial availability.
Targeted manipulation of genes is a widely used approach to study the impact of inammatory pathways related to IBD.With regard to intestinal brosis, several genetically induced models are available. The targeted disruption of the IL-10 gene in mice leads to a spontaneous chronic enterocolitis [10, 11]. While a rather mild colonic inammation is observed in IL-10-decient mice under pathogen-free con­ditions, animals under conventional housing conditions show mucosal inammation in the upper and lower intestinal tract as well as systemic signs of inammation such
+
as anemia [10]. Colitis manifestation is dependent on CD4
T cells and mediated by IFN-γ since anti-INF-γ antibody administration was elegantly shown to ameliorate the disease course in IL-10-decient colitic mice [12]. Colitis induction in this model can be accelerated and aggravated by oral administration of cyclooxygenase isoform-selective inhibitors such as piroxicam which act through a blockade of endogenous prostaglandin production [11]. Importantly, the molecular disease pat­tern of this model changes over time from a Th1-driven phenotype in early stages
+
cells
9 Animal Models andSources ofMesenchymal Cells inIntestinal Fibrosis
129
towards a predominant Th2-driven phenotype with increased IL-4 and IL-13 syn­thesis in later disease stages [13]. Of note, recent work has pointed out the relevance of IL-13in the pathogenesis of intestinal brosis [14, 15]. This fact together with the observation that increased ECM levels were found in the intestine of IL-10­decient mice, emphasize the applicability of this model to study intestinal bro­genesis [16].
TGF-β1 is a core mediator for initiation and perpetuation of brogenesis in gen­eral and has also been identied as a key driver for intestinal brogenesis in IBD patients [17, 18]. Accordingly, genetically-engineered mice owing a TGF-β overex­pression represent a promising research tool to study brogenesis. Vallance etal. demonstrated that mice treated by TGF-β1 gene transfer via rectal enema delivery will rst develop inammatory alterations of the intestine within 2 weeks [19]. Subsequently, these animals present with marked brotic alterations including mas­sive collagen deposition, myobroblast inltration and colonic wall thickening and obstruction in up to 50% of treated mice. Fibrotic alterations in this model appear focally along the colon and mortality rates of this model are below 10% [19].
The cytokine monocyte chemoattractant protein 1 (MCP-1) is well known to play a crucial role in mediating brotic alterations in different organs such as the lung, the kidney and the liver [20–22]. MCP-1 is capable to attract different cell types including monocytes, T and NK cells. Furthermore, MCP-1 expressionw as found to be enhanced within the submucosa and muscularis propria of CD patients as compared to healthy controls [23]. Intramural gene transfer via an adenovector endoding for murine MCP-1 resulted in transmural inammation and induction of brosis reected by an increased collagen accumulation from day 3–21 post gene transfer [24]. Furthermore, probrotic markers such as TGF-β1 and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) were found to be increased at day 7 post
−/−
vector transfer. In contrast, T and B cell-decient RAG2
mice did not respond with collagen deposition upon gene transfer pointing at a crucial role for lympho­cytes in this model [24].
Chemically-induced models of brosis depend on the external administration of variable agents that induce an inammatory response of the intestine through intes­tinal epithelial injury or direct activation of immune cells. As a consequence of a epithelial barrier defect, microbiota can penetrate the colonic wall, interact with local immune cells of the lamina propria and thus initiate or maintain inammation which in turn may futher fuel brogenesis.
The trinitrobenzene sulfonic (TNBS) acid-induced intestinal brosis model is one of the most commonly applied chemically-induced models [25]. Rectally administered TNBS (usually diluted in ethanol to induce epithelial damage) acts as a hapten causing a T cell dependent transmural inammation [26, 27]. Repetitive rectal TNBS application of increasing doses results in a chronic colitis accompanied by intestinal brosis that may become evident by luminal stenosis and bowel dilata­tion [28]. In this chronic stage, the disease pattern is characterized by elevated levels of Th2 cytokines and TGF-β1. More specically, TGF-β1 expression was shown to be at least partially dependent on IL-13 [4]. In addition, application of an antisense oligonucleotide directed against the pro-inammatory transcription factor NF-κB
130
D. Bettenworth
was shown to ameliorate TNBS-induced brogenesis indicating that this modell is NF-κB dependent [29]. However, this effect may also be mediated by the anti­inammatory action of a therapeutic NF-κB blockade. Finally, mast cells and neu­ropeptides such as substance P are linked to brogenesis in the TNBS-induced colitis model since a mast cell blockade and neuropeptide antagonism were shown to result in a reducted brotic alterations of TNBS-challenged mice [30, 31]. A major limitation of the TNBS model is that brotic alterations are restricted to areas of TNBS installation and depend on the hapten dosing. While low doses may be insufcient to induce an appropriate degree of inammation, higher doses may cause high mortality rates. In addition, appropriately susceptible mouse strains are required to successful apply the TNBS-induced model. Regrettably, the commonly used C57Bl/6 WT mice does not appear to be particular susceptible to TNBS­induced brosis.
Oral administration of dextran sodium sulfate (DSS), a complex polymer of glu­cose, in the drinking water of mice results in a experimental colitis, mediated by toxic DSS effects leading to impaired proliferation of epithelial cells, break down of the epithelial barrier and recruitment of macrophages [25]. In addition, chronic DSS administration in some mouse strains induces marked brotic alterations with increased TGF-β and MMP-2/-9 expression [32, 33]. One major advantage of this chemically-induced brosis model is the easy route of DSS-application as com­pared to TNBS for example. On the other hand, the degree of intestinal brosis is modest and brosis will not be found in the ileum. The penetrance rate of brosis may be increased by extending or repetition of DSS administration [5], however, due to its toxic nature, the overall transferability of this model to human IBD may be limited.
Several years ago, it was reported that peroxynitrite, an oxidant and nitrating agent, rectally administered into the colons of rats lead to narrowing of the colonic lumen and signs of stenosis at day 21 [34]. Furthermore, histopathological analyses showed transmural colitis and thickening of the muscularis mucosae and muscularis propria reecting manifest brosis.
The vast majority of animal models for IBD were intended to study the role of the intestinal immune responses during inammation. Later on, some of these mod­els such as the DSS-induced colitis model were extended to assess the chronic phase of intestinal inammation. Additionally, this extension allows for investigation of intestinal brosis. The T cell transfer-induced colitis represents the most commonly used immune-mediated model for intestinal brosis. In this model, the intravenous
high
injection of naïve CD45RB
CD4+ T cells into immunodecient SCID mice results in a strong transmural colitis [35, 36]. In addition to an inammatory cell inltrate containing neutrophils, lymphocytes and macrophages, a narrowing of the intestinal lumen can be observed due to the accumulation of stromal cells reecting brotic alterations of the T cell transfer model [37]. This observation has been conrmed by histopathological studies, however, the overall brosis development in this model appears to be rather less frequent.
There is a growing body of evidence, that microbioata is a key driver of intestinal
brogenesis in human IBD patients as well as in experimental models of brosis [38].
9 Animal Models andSources ofMesenchymal Cells inIntestinal Fibrosis
131
Accordingly, several experimental approaches have been used to establish bacteria- induced models of brosis.
Peptidoglycan-polysaccaride (PG-PS), a bacterial cell wall polymer induces a transmural colitis when injected into the colonic wall of rats [39]. After a chronic inammatory phase of 3weeks, a brotic thickening of the intestinal wall with asso­ciated adhesions can be observed. Furthermore, increased tissue levels of TGF-β1 and IGF-I were found [40]. While this model allows reproducible investigation of different stages of brosis, it is technically challenging and is only partially trans­ferred to mice by now [41].
Similarly to the latter model, a fecal suspension of various aerobic (Lactobacillus ssp., Enterobacter aerogenes, Klebsiella pneumoniae and Streptococcus viridans) and anerobic bacterial strains (Clostridium ramnosum, Bacteroides fragilis and Bacteroides uniformis) was found to induce brosis when injected into the colonic wall of rats. Treated animals showed signs of chronic inammation and brosis with stricture development. Additionally, TGF-β1 and collagen synthesis were sig­nicantly enhanced [42]. Subsequent work demonstrated an increased production of TGF-β1 stimulated Smad2/3 phosphorylation and enhanced ALK5, TIMP-1, and α2 type 1 collagen gene expression [43]. Slight modications of this models indi- cated that inoculation with single anaerobic strains such as Clostridium ramosum or Bacteroides fragilis (but not with aerobic) strains was able to induce collagen depo­sition. These observations emphasize the impact of commensal gut microbiota on TGF-β1 and collagen production and the impact on intestinal brogenesis in general.
In addition, oral administration of live bacteria such as Salmonella enterica serovar Typhimurium can be used to establish intestinal brosis in mice. In this model, 24hours after antibiotic pre-treatment with streptomycin, the ingestion of Salmonella typhimurium results in colitis development, which can be accompanied by marked brotic alterations of the cecum and colon that further aggravated over the following 3weeks [44]. Functionally, it was shown that the Salmonella viru­lence factors Salmonella pathogenicity islands (SPI)-1 and SPI-2 are essentiell for brosis induction in this model. Furthermore, enhanced production of TGF-β1, con­nective tissue growth factor (CTGF) and IGF-I was documented accompanied by increased broblast accumulation [44]. Targeted elimination of the inammatory stimulus by antibiotic treatment may be used to assess the specic impact of inam­mation on brogenesis at different time points. This model is easy to perform and shows good reproducibility in various mouse strains as well as in genetically­modied mice. However, the relevance to human brostenotic IBD may be limited by the fact that Salmonella infection does not contribute to stricture development in human CD patients.
A specic subset of E. coli with acquired virulence factors was identied being capable to adhere and invade the intestinal epithelium which in turn leads to an inammatory response in human CD patients. 21days after oral gavage of so-called adherent invasive E.coli (AIEC) to CD1 mice pretreated with streptomycin, a trans­mural inammation of the caecum with edema and crypt hyperplasia was observed. Similarly treated C57Bl/6 mice additionally developed submucosal ulcerations as
132
D. Bettenworth
well as thickened mucosa indicative of crypt hyperplasia. Macroscopic assessment of ileal specimen from both strains revealed epithelial destruction and crypt ulcer­ations. Colonic and ileal inammation in CD1 and C57Bl/6 mice was characterized by a signicant increase in TNF-α, INF-γ and IL-17. Furthermore, immunohisto­logical analyses using Masson’s trichrome and picrosirius staining visualized pro­gressive ECM deposition being more pronounced in caecal than in colonic samples from AIEC-treated mice. In accordance with these histomorphological changes, increased expression levels of TGF-β, CTGT and IGF1 were detected [45].
Based on the phenomenon that colonic exposure to therapeutic radiation can result in relevant intestinal brosis, radiation-induced models of intestinal brosis were invented. Radiation-induced thickening of the bowel wall is characterized by an enlarged submucosa, increased proliferation rates of broblasts and smooth mus­cle cells as well as enhanced accumulation of collagen and other ECM elements [46]. Core features of radiation-induced intestinal brosis are vascular sclerosis with endothelial dysfunction and chronic ulcers. Of note, the degree of brosis can increase up to 26weeks following radiation and is mainly inuenced by the applied radiation dose, fraction size as well as the time between several radiation procedures [47, 48]. Two different experimental settings for this approach have been proposed. In the rst model, a small bowel segment is resected, exernally irradiated and the re-implanted into the animal [49, 50]. In an alternative approach, a 4-cm segment of the distal ileum is transferred into the scrotum after a orchiectomy has been per­formed; since this location is easy accessable for radiation [51]. The radiation results in an acute inammatory response with colitis und ulcer development and induction of brotic alterations in the stromal compartment. This multicellular­mediated response is partially dependent on inammation with microvascular insults being an early stimulus that is accompanied by subsequent hypoxia [52]. Subsequently, common brotic alterations including probrotic cytokine produc­tion such as TGF-β1 and CTGF, broblast proliferation and increased collagen pro­duction are observed [53]. In addition, activation of mast cells, Rho-associated kinase (ROCK) signaling pathways, endothelial dysfunction and activation of capsaicin- sensitive nerves represent additional, more specic response of the irradi­ated bowel [54].
It is a well-known clinical observation that up to 40% of CD patients being treated by intestinal resection will suffer from a symptomatic recurrence within the rst 3years after surgery, that may further culminate in postoperative brosis devel­opment and anastomotic stenosis [55]. Recently, an animal model for postoperative brosis has been described. Rigby etal. performed a ileocecal resection in IL-10­decient mice and WT mice. In contrast to the WT control group, IL-10-decient mice developed inammation-driven brosis at the proximal site of the anastomosis [56]. Importantly, germ-free housed IL-10-decient mice did not develop brosis after ileocecal resection indicating that the innate immunity is part of this model [57]. Furthermore, in a model of colonic resection, an enhanced myobroblast growth and differentiation at the anastomosis was observed [58]. In addition to re­stenosis of the anastomosis, occurrence of postsurgical adhesions reect another
9 Animal Models andSources ofMesenchymal Cells inIntestinal Fibrosis
aspect of postoperative brosis. Serosal abrasion of the murine cecum can be easily performed and adhesions could be veried within 6days [59]. Interestingly, execu­tors of the adaptive immune system such as CD4+ Th1 are involved in adhesion development by regulating chemokine production and leukocyte trafcking. In addition, a protective role of microbial polysaccharides and IL-10 regarding adhe­sion formation was observed [60, 61].
Recently, an experimental model of tracheal transplantation to study bronchiol­itis obliterans was transferred into a heterotopic intestinal transplant model to elu- cidate intestinal brosis. To this aim, 3 cm small bowel resections of rats were transplanted into the neck of recipient rats [62]. The intestinal transplants were shown to be viable for 3weeks. Beginning from day 2 after transplantation, loss of crypt architecture and lymphocyte inltration was observed and resulted in brotic narrowing of the intestinal lumen by day 21. Additionally, collagen expression, TGF-β synthesis and IL-13 production were signicantly increased over time [62]. While this model is considered to be rather articial, it was shown to be appropriate to evaluate anti-brotic potential drug candidates [63, 64].
133
9.2 Relevance andApplicability ofExperimental Models
ofFibrosis toStudy Human Fibrostenotic Inammatory Bowel Disease
Clinical trials in brostenotic IBD patients are challenging due to several reasons. By now, no ideal target for intestinal brosis has been identied and the optimal timing of a anti-brotic treatment is unknown. In addition, appropriate biomarkers to facilitate an early risk stratication are not available and the ideal route of admin­istration for anti-brotic drug candidates is unknown [65]. Therefore, the use of animal models is inevitable to further elucidate intestinal brogenesis and to evalu­ate novel diagsnotic and therapeutic approaches in order to improve quality of life of IBD patients with brostenotic complications.
Depending on the specic study hypothesis, one has to decide which model to apply. Of note, most of the above mentioned models have been established to study different aspects of the immune systems in the context of experimental colitis. Giving the experimental set-up, it is obvious that these models do not imply all pathogenic components of human patients suffering from intestinal brosis. For example, as chemically-induced models of brosis largely depend on an impaired epithelial barrier function upon administration of toxic substances, these models may not reect the physiological insult that leads to intestinal brosis but may be particulary suitable to study the role of the innate immune system during brosis development. Furthermore, with regard to the commonly used TNBS model, vari­ability of successful colitis induction depending on the optimal amount of TNBS may be challenging. Genetically-induced models of brosis usually feature single gene modication that do not reect the underlying polygenetic alterations in IBD